PPARGC1A and metabolic dysfunction-associated steatotic liver disease: Derdak et al. showed that inhibiting p53 transcriptional activity partially reduced steatosis, associated oxidative stress, and apoptosis in a mouse model of NAFLD by downregulating miR-34a and activating the SIRT1/PGC1α/PPARα axis [121].